Is linezolid a risk factor for Gram-negative bacillus infections in intensive care unit patients? A comparative study with vancomycin

References

• Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789–97.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30:388–94.
   PubMed Web of Science ®Google Scholar
• ATS Board of Directors and the IDSA Guideline Committee. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171: 388–416.
   Google Scholar
• Rodriguez CO, Alvarez LF, Alvarez SB, Oltra CR, Barcenilla GF, Cereijo, . Use of antibiotics for the treatment of multiresistant Gram-positive cocci infections in critical patients. Med Intensiva 2008;32:263–71.
   Google Scholar
• Rodriguez O, Alvarez F, Oltra R, Cereijo E, Latorre MM, Martinez H. Use of linezolid in critically ill patients admitted to intensive care units. Rev Esp Quimioter 2009;22:68–75.
   PubMed Web of Science ®Google Scholar
• Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475–80.
   PubMed Web of Science ®Google Scholar
• Lamer C, de Beco V, Soler P, Calvat S, Fagon JY, Dombret MC, . Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993;37:281–6.
   PubMed Web of Science ®Google Scholar
• MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003; 51(Suppl 2):ii17–25.
   PubMedGoogle Scholar
• Stein GE, Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin 2010;26: 571–88.
   PubMed Web of Science ®Google Scholar
• Kofteridis DP, Malliotakis P, Maraki S, Christofaki M, Samonis G. Impact of prolonged treatment with linezolid on the human gut flora. Int J Infect Dis 2009;13:e313–5.
   Google Scholar
• Lode H, von der Höh N, Ziege S, Borner K, Nord CE. Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis 2001;33:899–903.
   PubMedGoogle Scholar
• Pultz NJ, Stiefel U, Donskey CJ. Effects of daptomycin, linezolid, and vancomycin on establishment of intestinal colonization with vancomycin-resistant enterococci and extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae in mice. Antimicrob Agents Chemother 2005;49:3513–6.
   Google Scholar
• Charbonneau P, Parienti JJ, Thibon P, Ramakers M, Daubin C, du Cheyron D, . Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 2006;42:778–84.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008;8:53–66.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least 4 grams/day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330–6.
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, . Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009;48: 203–12.
   PubMed Web of Science ®Google Scholar
• Swoboda S, Ober MC, Lichtenstern C, Saleh S, Schwenger V, Sonntag HG, . Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010;66:291–8.
   PubMed Web of Science ®Google Scholar
• Wu VC, Wang YT, Wang CY, Tsai IJ, Wu KD, Hwang JJ, . High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006;42:66–72.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y, . Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents 2010;36:179–81.
   PubMed Web of Science ®Google Scholar
• Garrabou G, Soriano A, Lopez S, Guallar JP, Giralt M, Villarroya F, . Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother 2007;51:962–7.
   PubMed Web of Science ®Google Scholar
• Soriano A, Miro O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med 2005;353:2305–6.
   PubMed Web of Science ®Google Scholar